Second Primary Cancers following Colorectal Cancer in Sicily, Italy.
cancer mortality
cancer survivors
colorectal cancer
multiple cancers
second primary cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Oct 2022
24 Oct 2022
Historique:
received:
22
09
2022
revised:
19
10
2022
accepted:
20
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
Cancer survivors are at risk of developing second primary cancers (SPC). We investigated the risk of SPC in colorectal cancer (CRC) survivors in Sicily, Southern Italy. We analyzed data from the Eastern Sicily cancer registry covering 2.5 million people diagnosed and followed up between 2003 and 2017. We calculated the standardized incidence ratio (SIR) and 95% confidence interval (CI) of SPC overall and by cancer type, using the general Sicily population rates as reference. A total of 19,040 cases of CRC and 1453 cases of SPC were included in the analysis. Mean age of occurrence of SPC was 68.1. The SIR for any SPC was 1.11 (95% CI 1.05-1.17); it was higher in women (1.18; 95% CI 1.08-1.29) than in men (1.07; 95% CI 0.97-1.14, In this population, CRC survivors have an 11% higher risk of developing a SPC than the general population, particularly cancers of the ovary, kidney, endometrium, bladder and stomach. Follow-up for SPC is required, especially during the first 5 years from CRC diagnosis.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer survivors are at risk of developing second primary cancers (SPC). We investigated the risk of SPC in colorectal cancer (CRC) survivors in Sicily, Southern Italy.
METHODS
METHODS
We analyzed data from the Eastern Sicily cancer registry covering 2.5 million people diagnosed and followed up between 2003 and 2017. We calculated the standardized incidence ratio (SIR) and 95% confidence interval (CI) of SPC overall and by cancer type, using the general Sicily population rates as reference.
RESULTS
RESULTS
A total of 19,040 cases of CRC and 1453 cases of SPC were included in the analysis. Mean age of occurrence of SPC was 68.1. The SIR for any SPC was 1.11 (95% CI 1.05-1.17); it was higher in women (1.18; 95% CI 1.08-1.29) than in men (1.07; 95% CI 0.97-1.14,
CONCLUSIONS
CONCLUSIONS
In this population, CRC survivors have an 11% higher risk of developing a SPC than the general population, particularly cancers of the ovary, kidney, endometrium, bladder and stomach. Follow-up for SPC is required, especially during the first 5 years from CRC diagnosis.
Identifiants
pubmed: 36358623
pii: cancers14215204
doi: 10.3390/cancers14215204
pmc: PMC9657763
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Genitourin Cancer. 2016 Aug;14(4):e363-9
pubmed: 27105723
Curr Vasc Pharmacol. 2014;12(5):735-8
pubmed: 24350926
Health Informatics J. 2019 Mar;25(1):149-160
pubmed: 28438105
Cancer. 1993 Feb 1;71(3):677-85
pubmed: 8431847
Int J Colorectal Dis. 2022 Mar;37(3):541-551
pubmed: 35152308
Gut. 2002 May;50(5):647-52
pubmed: 11950810
Int J Mol Sci. 2017 Jan 19;18(1):
pubmed: 28106826
J Clin Gastroenterol. 2007 Mar;41(3):291-6
pubmed: 17426469
Int J Cancer. 2016 Sep 1;139(5):1081-90
pubmed: 27098183
Oncology (Williston Park). 2019 Jul 16;33(7):
pubmed: 31365752
Nat Rev Clin Oncol. 2021 Apr;18(4):230-243
pubmed: 33219329
Radiother Oncol. 2016 Dec;121(3):402-413
pubmed: 27639892
Int J Cancer. 2014 Oct 15;135(8):1756-63
pubmed: 24945890
Int J Med Sci. 2020 Jan 15;17(3):280-291
pubmed: 32132862
Int J Gynecol Cancer. 2021 Aug;31(8):1137-1144
pubmed: 34083378
Surg Oncol. 2017 Dec;26(4):535-543
pubmed: 29113675
Epidemiol Prev. 2013 Jul-Oct;37(4-5 Suppl 1):1-152
pubmed: 24259384
BMC Cancer. 2021 Nov 12;21(1):1210
pubmed: 34772394
BMC Cancer. 2014 Apr 18;14:272
pubmed: 24742063
IARC Sci Publ. 1987;(82):1-406
pubmed: 3329634
Gastroenterology. 2000 Sep;119(3):837-53
pubmed: 10982778
Stud Health Technol Inform. 2020 Jun 16;270:1191-1192
pubmed: 32570574
BMC Cancer. 2021 Sep 23;21(1):1045
pubmed: 34556087
Eur J Cancer. 2020 Jan;124:142-151
pubmed: 31765989
Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):643-649
pubmed: 30541751
Br J Cancer. 2006 Aug 7;95(3):390-2
pubmed: 16804519
Gerontology. 2014;60(6):508-18
pubmed: 25170545
Sci Rep. 2021 Feb 2;11(1):2759
pubmed: 33531585
Eur J Clin Microbiol Infect Dis. 2009 May;28(5):437-46
pubmed: 18958508
Anticancer Res. 2020 Jul;40(7):3811-3818
pubmed: 32620620
Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1543-9
pubmed: 18559572
PLoS One. 2015 Nov 16;10(11):e0143067
pubmed: 26571301
Curr Med Res Opin. 2013 Sep;29(9):1055-65
pubmed: 23777310
Int J Colorectal Dis. 2020 Jul;35(7):1273-1282
pubmed: 32347342
BJS Open. 2020 Aug;4(4):685-692
pubmed: 32543788
Cancer. 2021 Aug 15;127(16):3029-3030
pubmed: 34086348
Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1332-52
pubmed: 12433710
ESMO Open. 2017 May 2;2(2):e000172
pubmed: 28761745
Medicine (Baltimore). 2015 Jul;94(26):e1079
pubmed: 26131831